Comparative Randomized, Single‐Dose, Two‐Way Crossover Open‐Label Study to Determine the Bioequivalence of Two Formulations of Dalfampridine Tablets. Issue 3 (11th May 2018)

• Record Type: Journal Article
• Authors: Al Bawab, Abdel Qader; Alkhalidi, Bashar A.; Albarahmieh, Esra'a; Qassim, Sami M.A.; Al‐Saifi, Mohammad A. D.
• Is Part Of: Clinical pharmacology in drug development. Volume 8:Issue 3(2019)
• Page Start: 355
• Page End: 360
• Publication Date: 2018-05-11
• Subjects: dalfampridine -- multiple sclerosis -- bioequivalence -- pharmacokinetics -- guidelines; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.574
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Dalfampridine is a medication that is approved by the US Food and Drug Administration to improve walking impairments in patients with multiple sclerosis (MS). The branded dalfampridine is enormously expensive; hence, the availability of generic dalfampridine will provide better access to the medication, especially for uninsured patients with MS. Bioequivalence studies are demanded by the regulatory authorities to allow the marketing of new generics of dalfampridine. The aim of this study was to assess the bioavailability of the generic (test) and branded (reference) formulations of 10 mg dalfampridine of extended‐release tablets after oral administration to healthy adults under fed conditions. The current report methodology was based on a comparative, randomized, single‐dose, 2‐way crossover open‐label study design. Twenty‐seven subjects were given a single dose of the test dalfampridine tablet and completed the clinical study. The pharmacokinetic parameters Cmax and AUC0→t, Kel, AUC0→∞, tmax, and t1/2el were estimated to prove bioequivalence. The confidence intervals for the log‐transformed test/reference ratios for dalfampridine 100.96% (97.09%–104.97%) and 99.77% (95.81%–103.87%) for Cmax and AUC0→∞, respectively, were within the allowed limit specified by the regulatory authorities (80%–125%). Hence, clinically, the test tablet can be prescribed as an alternative to the reference for the indication of improving walking impairments in patients with MS.